4
Changes in Ownership
Damora Therapeutics, Inc. Filed Acc 0000950170-25-002811
Chief Executive Officer sold 1,341 shares at $5.60 ($7,510)
- Chief Executive Officer acquired 2,640 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Schambye Hans T. Chief Executive Officer | 2025-01-03 | Option exercise | +2,640 | 4,738 | D | ||
| Schambye Hans T. Chief Executive Officer | 2025-01-03 | Sale | −1,341 | $5.60 | $7,510 | 3,397 | D |
| Derivatives | |||||||
| Schambye Hans T. Chief Executive Officer | 2025-01-03 | Option exercise · Restricted Stock Units | −2,640 | 5,360 | D | ||
| Schambye Hans T. Chief Executive Officer | 2025-01-03 | Grant or award · Stock Option (right to buy) | +16,400 | 16,400 | D | ||
| Open-market sales · 1,341 sh · avg $5.60 · $7,510 | |||||||
Loading xslF345X05/ownership.xml…